AUTHOR=Fan Shipei , Shi Xing-yu , Zhao Chao-fu , Chen Zhen , Ying Jia , Yu Song-ping , Li Jun , Li Xia 

TITLE=Efficacy and safety of single-dose intravitreal dexamethasone implant in non-infectious uveitic macular edema: A systematic review and meta-analysis

JOURNAL=Frontiers in Medicine

VOLUME=Volume 10 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1126724

DOI=10.3389/fmed.2023.1126724

ISSN=2296-858X

ABSTRACT=Purpose: We conducted a systematic review and meta-analysis to investigate the efficacy and safety of single-dose intravitreal dexamethasone (DEX) implant for treating non-infectious uveitic macular edema (UME).
Methods: Studies including clinical outcomes of DEX implant in UME were comprehensively searched in Pubmed, Embase and Cochrane databases for potential studies from inception to July 2022. The primary outcomes were best corrected visual acuity (BCVA) and central macular thickness (CMT) during follow-up period. Stata 12.0 was used to perform statistical analyses.
Results: Six retrospective studies and one prospective investigation involving 201 eyes were ultimately included. Significantly improved BCVA was observed from baseline to 1 month (WMD= -0.15, 95%CI= -0.24, -0.06), 3 months (WMD= -0.22, 95%CI= -0.29, -0.15) and 6 months (WMD= -0.24, 95%CI= -0.35, -0.13), after single-dose DEX implant. When considering CMT, macular thickness of 1 month (WMD= -179.77, 95%CI= -223.45, -136.09), 3 months (WMD= -179.13, 95%CI= -232.63, -125.63) and 6 months (WMD= -140.25, 95%CI= -227.61, -52.88) decreased in comparison to baseline, with statistical significance.
Conclusion: Based on current results, this meta-analysis confirmed favorable visual prognosis and anatomical improvement in UME patients, after receiving the single-dose DEX implant. The most common adverse event is increased intraocular pressure, which could be controlled with topical medications.